Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 89

1.

The impact of CFTR modulator therapies on CF airway microbiology.

Rogers GB, Taylor SL, Hoffman LR, Burr LD.

J Cyst Fibros. 2019 Aug 12. pii: S1569-1993(19)30829-X. doi: 10.1016/j.jcf.2019.07.008. [Epub ahead of print] Review.

PMID:
31416774
2.

Making the case for ACEs: adverse childhood experiences, obesity, and long-term health.

Javier JR, Hoffman LR, Shah SI; Pediatric Policy Council.

Pediatr Res. 2019 Jul 22. doi: 10.1038/s41390-019-0509-2. [Epub ahead of print] No abstract available.

PMID:
31330528
3.

Heterogeneity in surface sensing suggests a division of labor in Pseudomonas aeruginosa populations.

Armbruster CR, Lee CK, Parker-Gilham J, de Anda J, Xia A, Zhao K, Murakami K, Tseng BS, Hoffman LR, Jin F, Harwood CS, Wong GC, Parsek MR.

Elife. 2019 Jun 10;8. pii: e45084. doi: 10.7554/eLife.45084.

4.

The use of antimicrobial susceptibility testing in pediatric cystic fibrosis pulmonary exacerbations.

Cogen JD, Whitlock KB, Gibson RL, Hoffman LR, VanDevanter DR.

J Cyst Fibros. 2019 May 28. pii: S1569-1993(19)30764-7. doi: 10.1016/j.jcf.2019.05.012. [Epub ahead of print]

PMID:
31147301
5.

Human and Extracellular DNA Depletion for Metagenomic Analysis of Complex Clinical Infection Samples Yields Optimized Viable Microbiome Profiles.

Nelson MT, Pope CE, Marsh RL, Wolter DJ, Weiss EJ, Hager KR, Vo AT, Brittnacher MJ, Radey MC, Hayden HS, Eng A, Miller SI, Borenstein E, Hoffman LR.

Cell Rep. 2019 Feb 19;26(8):2227-2240.e5. doi: 10.1016/j.celrep.2019.01.091.

6.
7.

Cerebrospinal Fluid Shunt Infection: Emerging Paradigms in Pathogenesis that Affect Prevention and Treatment.

Simon TD, Schaffzin JK, Stevenson CB, Willebrand K, Parsek M, Hoffman LR.

J Pediatr. 2019 Mar;206:13-19. doi: 10.1016/j.jpeds.2018.11.026. Epub 2018 Dec 6. No abstract available.

PMID:
30528757
8.

How low can we go? The implications of low bacterial load in respiratory microbiota studies.

Marsh RL, Nelson MT, Pope CE, Leach AJ, Hoffman LR, Chang AB, Smith-Vaughan HC.

Pneumonia (Nathan). 2018 Jul 5;10:7. doi: 10.1186/s41479-018-0051-8. eCollection 2018. Review.

9.

Understanding the Role of Staphylococcus aureus in Non-Cystic Fibrosis Bronchiectasis: Where Are We Now?

Somayaji R, Ramos KJ, Hoffman LR.

Ann Am Thorac Soc. 2018 Mar;15(3):310-311. doi: 10.1513/AnnalsATS.201712-944ED. No abstract available.

10.

Chronic Azithromycin Use in Cystic Fibrosis and Risk of Treatment-Emergent Respiratory Pathogens.

Cogen JD, Onchiri F, Emerson J, Gibson RL, Hoffman LR, Nichols DP, Rosenfeld M.

Ann Am Thorac Soc. 2018 Jun;15(6):702-709. doi: 10.1513/AnnalsATS.201801-012OC.

PMID:
29474110
11.

Adaptation of commensal proliferating Escherichia coli to the intestinal tract of young children with cystic fibrosis.

Matamouros S, Hayden HS, Hager KR, Brittnacher MJ, Lachance K, Weiss EJ, Pope CE, Imhaus AF, McNally CP, Borenstein E, Hoffman LR, Miller SI.

Proc Natl Acad Sci U S A. 2018 Feb 13;115(7):1605-1610. doi: 10.1073/pnas.1714373115. Epub 2018 Jan 29.

12.

Ferreting Out the Role of Infection in Cystic Fibrosis Lung Disease.

Hoffman LR, Hajjar AM.

Am J Respir Crit Care Med. 2018 May 15;197(10):1243-1244. doi: 10.1164/rccm.201801-0053ED. No abstract available.

PMID:
29357264
13.

How can the cystic fibrosis respiratory microbiome influence our clinical decision-making?

Rogers GB, Bruce KD, Hoffman LR.

Curr Opin Pulm Med. 2017 Nov;23(6):536-543. doi: 10.1097/MCP.0000000000000419. Review.

14.

Restoring Cystic Fibrosis Transmembrane Conductance Regulator Function Reduces Airway Bacteria and Inflammation in People with Cystic Fibrosis and Chronic Lung Infections.

Hisert KB, Heltshe SL, Pope C, Jorth P, Wu X, Edwards RM, Radey M, Accurso FJ, Wolter DJ, Cooke G, Adam RJ, Carter S, Grogan B, Launspach JL, Donnelly SC, Gallagher CG, Bruce JE, Stoltz DA, Welsh MJ, Hoffman LR, McKone EF, Singh PK.

Am J Respir Crit Care Med. 2017 Jun 15;195(12):1617-1628. doi: 10.1164/rccm.201609-1954OC.

15.

Characterization of Inpatient Cystic Fibrosis Pulmonary Exacerbations.

Cogen JD, Oron AP, Gibson RL, Hoffman LR, Kronman MP, Ong T, Rosenfeld M.

Pediatrics. 2017 Feb;139(2). pii: e20162642. doi: 10.1542/peds.2016-2642.

16.

Establishing Equipoise: National Survey of the Treatment of Pediatric Para-Pneumonic Effusion and Empyema.

Richards MK, Mcateer JP, Edwards TC, Hoffman LR, Kronman MP, Shaw DW, Goldin AB.

Surg Infect (Larchmt). 2017 Feb/Mar;18(2):137-142. doi: 10.1089/sur.2016.134. Epub 2016 Nov 29.

17.

LasR Variant Cystic Fibrosis Isolates Reveal an Adaptable Quorum-Sensing Hierarchy in Pseudomonas aeruginosa.

Feltner JB, Wolter DJ, Pope CE, Groleau MC, Smalley NE, Greenberg EP, Mayer-Hamblett N, Burns J, Déziel E, Hoffman LR, Dandekar AA.

MBio. 2016 Oct 4;7(5). pii: e01513-16. doi: 10.1128/mBio.01513-16.

18.

The CF gastrointestinal microbiome: Structure and clinical impact.

Rogers GB, Narkewicz MR, Hoffman LR.

Pediatr Pulmonol. 2016 Oct;51(S44):S35-S44. doi: 10.1002/ppul.23544. Review.

19.

Cystic Fibrosis: Microbiology and Host Response.

Zemanick ET, Hoffman LR.

Pediatr Clin North Am. 2016 Aug;63(4):617-36. doi: 10.1016/j.pcl.2016.04.003. Review.

20.

The microbiota in bronchoalveolar lavage from young children with chronic lung disease includes taxa present in both the oropharynx and nasopharynx.

Marsh RL, Kaestli M, Chang AB, Binks MJ, Pope CE, Hoffman LR, Smith-Vaughan HC.

Microbiome. 2016 Jul 7;4(1):37. doi: 10.1186/s40168-016-0182-1.

21.

Staphylococcus aureus Protein A Mediates Interspecies Interactions at the Cell Surface of Pseudomonas aeruginosa.

Armbruster CR, Wolter DJ, Mishra M, Hayden HS, Radey MC, Merrihew G, MacCoss MJ, Burns J, Wozniak DJ, Parsek MR, Hoffman LR.

MBio. 2016 May 24;7(3). pii: e00538-16. doi: 10.1128/mBio.00538-16.

22.

Pyomelanin-producing Pseudomonas aeruginosa selected during chronic infections have a large chromosomal deletion which confers resistance to pyocins.

Hocquet D, Petitjean M, Rohmer L, Valot B, Kulasekara HD, Bedel E, Bertrand X, Plésiat P, Köhler T, Pantel A, Jacobs MA, Hoffman LR, Miller SI.

Environ Microbiol. 2016 Oct;18(10):3482-3493. doi: 10.1111/1462-2920.13336. Epub 2016 Jun 2.

23.

Metagenomic evidence for taxonomic dysbiosis and functional imbalance in the gastrointestinal tracts of children with cystic fibrosis.

Manor O, Levy R, Pope CE, Hayden HS, Brittnacher MJ, Carr R, Radey MC, Hager KR, Heltshe SL, Ramsey BW, Miller SI, Hoffman LR, Borenstein E.

Sci Rep. 2016 Mar 4;6:22493. doi: 10.1038/srep22493.

24.

Optimized In Vitro Antibiotic Susceptibility Testing Method for Small-Colony Variant Staphylococcus aureus.

Precit MR, Wolter DJ, Griffith A, Emerson J, Burns JL, Hoffman LR.

Antimicrob Agents Chemother. 2016 Jan 4;60(3):1725-35. doi: 10.1128/AAC.02330-15.

25.

Cystic fibrosis-adapted Pseudomonas aeruginosa quorum sensing lasR mutants cause hyperinflammatory responses.

LaFayette SL, Houle D, Beaudoin T, Wojewodka G, Radzioch D, Hoffman LR, Burns JL, Dandekar AA, Smalley NE, Chandler JR, Zlosnik JE, Speert DP, Bernier J, Matouk E, Brochiero E, Rousseau S, Nguyen D.

Sci Adv. 2015 Jul;1(6). pii: e1500199. Epub 2015 Jul 31.

26.

The pediatric microbiome and the lung.

Tracy M, Cogen J, Hoffman LR.

Curr Opin Pediatr. 2015 Jun;27(3):348-55. doi: 10.1097/MOP.0000000000000212. Review.

27.

Toward making inroads in reducing the disparity of lung health in Australian indigenous and new zealand māori children.

Chang AB, Marsh RL, Upham JW, Hoffman LR, Smith-Vaughan H, Holt D, Toombs M, Byrnes C, Yerkovich ST, Torzillo PJ, O'Grady KA, Grimwood K.

Front Pediatr. 2015 Feb 13;3:9. doi: 10.3389/fped.2015.00009. eCollection 2015. Review. No abstract available.

28.

Emerging drugs for bronchiectasis: an update.

Chang AB, Marsh RL, Smith-Vaughan HC, Hoffman LR.

Expert Opin Emerg Drugs. 2015 Jun;20(2):277-97. doi: 10.1517/14728214.2015.1021683. Epub 2015 Mar 3. Review.

PMID:
25736583
29.

Cystic fibrosis mouse model-dependent intestinal structure and gut microbiome.

Bazett M, Honeyman L, Stefanov AN, Pope CE, Hoffman LR, Haston CK.

Mamm Genome. 2015 Jun;26(5-6):222-34. doi: 10.1007/s00335-015-9560-4. Epub 2015 Feb 27.

30.

Implications of multiple freeze-thawing on respiratory samples for culture-independent analyses.

Cuthbertson L, Rogers GB, Walker AW, Oliver A, Hoffman LR, Carroll MP, Parkhill J, Bruce KD, van der Gast CJ.

J Cyst Fibros. 2015 Jul;14(4):464-7. doi: 10.1016/j.jcf.2014.10.004. Epub 2014 Oct 24.

31.

Strength in diversity.

Wolter DJ, Hoffman LR.

Cell Host Microbe. 2014 Oct 8;16(4):427-9. doi: 10.1016/j.chom.2014.09.018.

32.

Directly sampling the lung of a young child with cystic fibrosis reveals diverse microbiota.

Brown PS, Pope CE, Marsh RL, Qin X, McNamara S, Gibson R, Burns JL, Deutsch G, Hoffman LR.

Ann Am Thorac Soc. 2014 Sep;11(7):1049-55. doi: 10.1513/AnnalsATS.201311-383OC. Review.

33.

Pseudomonas aeruginosa in vitro phenotypes distinguish cystic fibrosis infection stages and outcomes.

Mayer-Hamblett N, Rosenfeld M, Gibson RL, Ramsey BW, Kulasekara HD, Retsch-Bogart GZ, Morgan W, Wolter DJ, Pope CE, Houston LS, Kulasekara BR, Khan U, Burns JL, Miller SI, Hoffman LR.

Am J Respir Crit Care Med. 2014 Aug 1;190(3):289-97. doi: 10.1164/rccm.201404-0681OC.

34.

Time between collection and storage significantly influences bacterial sequence composition in sputum samples from cystic fibrosis respiratory infections.

Cuthbertson L, Rogers GB, Walker AW, Oliver A, Hafiz T, Hoffman LR, Carroll MP, Parkhill J, Bruce KD, van der Gast CJ.

J Clin Microbiol. 2014 Aug;52(8):3011-6. doi: 10.1128/JCM.00764-14. Epub 2014 Jun 11.

35.

Pseudomonas aeruginosa phenotypes associated with eradication failure in children with cystic fibrosis.

Mayer-Hamblett N, Ramsey BW, Kulasekara HD, Wolter DJ, Houston LS, Pope CE, Kulasekara BR, Armbruster CR, Burns JL, Retsch-Bogart G, Rosenfeld M, Gibson RL, Miller SI, Khan U, Hoffman LR.

Clin Infect Dis. 2014 Sep 1;59(5):624-31. doi: 10.1093/cid/ciu385. Epub 2014 May 26.

36.

Gastrointestinal pathology in juvenile and adult CFTR-knockout ferrets.

Sun X, Olivier AK, Yi Y, Pope CE, Hayden HS, Liang B, Sui H, Zhou W, Hager KR, Zhang Y, Liu X, Yan Z, Fisher JT, Keiser NW, Song Y, Tyler SR, Goeken JA, Kinyon JM, Radey MC, Fligg D, Wang X, Xie W, Lynch TJ, Kaminsky PM, Brittnacher MJ, Miller SI, Parekh K, Meyerholz DK, Hoffman LR, Frana T, Stewart ZA, Engelhardt JF.

Am J Pathol. 2014 May;184(5):1309-22. doi: 10.1016/j.ajpath.2014.01.035. Epub 2014 Mar 15.

37.

Three clinically distinct chronic pediatric airway infections share a common core microbiota.

van der Gast CJ, Cuthbertson L, Rogers GB, Pope C, Marsh RL, Redding GJ, Bruce KD, Chang AB, Hoffman LR.

Ann Am Thorac Soc. 2014 Sep;11(7):1039-48. doi: 10.1513/AnnalsATS.201312-456OC.

38.

Escherichia coli dysbiosis correlates with gastrointestinal dysfunction in children with cystic fibrosis.

Hoffman LR, Pope CE, Hayden HS, Heltshe S, Levy R, McNamara S, Jacobs MA, Rohmer L, Radey M, Ramsey BW, Brittnacher MJ, Borenstein E, Miller SI.

Clin Infect Dis. 2014 Feb;58(3):396-9. doi: 10.1093/cid/cit715. Epub 2013 Oct 30.

39.

Fosfomycin and tobramycin in combination downregulate nitrate reductase genes narG and narH, resulting in increased activity against Pseudomonas aeruginosa under anaerobic conditions.

McCaughey G, Gilpin DF, Schneiders T, Hoffman LR, McKevitt M, Elborn JS, Tunney MM.

Antimicrob Agents Chemother. 2013 Nov;57(11):5406-14. doi: 10.1128/AAC.00750-13. Epub 2013 Aug 19.

40.

Staphylococcus aureus small-colony variants are independently associated with worse lung disease in children with cystic fibrosis.

Wolter DJ, Emerson JC, McNamara S, Buccat AM, Qin X, Cochrane E, Houston LS, Rogers GB, Marsh P, Prehar K, Pope CE, Blackledge M, Déziel E, Bruce KD, Ramsey BW, Gibson RL, Burns JL, Hoffman LR.

Clin Infect Dis. 2013 Aug;57(3):384-91. doi: 10.1093/cid/cit270. Epub 2013 Apr 26.

41.

Interpreting infective microbiota: the importance of an ecological perspective.

Rogers GB, Hoffman LR, Carroll MP, Bruce KD.

Trends Microbiol. 2013 Jun;21(6):271-6. doi: 10.1016/j.tim.2013.03.004. Epub 2013 Apr 16.

42.

Cystic fibrosis therapeutics: the road ahead.

Hoffman LR, Ramsey BW.

Chest. 2013 Jan;143(1):207-213. doi: 10.1378/chest.12-1639. Review.

43.

Reducing bias in bacterial community analysis of lower respiratory infections.

Rogers GB, Cuthbertson L, Hoffman LR, Wing PA, Pope C, Hooftman DA, Lilley AK, Oliver A, Carroll MP, Bruce KD, van der Gast CJ.

ISME J. 2013 Apr;7(4):697-706. doi: 10.1038/ismej.2012.145. Epub 2012 Nov 29.

44.

Emerging drugs for bronchiectasis.

Chang AB, Marsh RL, Smith-Vaughan HC, Hoffman LR.

Expert Opin Emerg Drugs. 2012 Sep;17(3):361-78. doi: 10.1517/14728214.2012.702755. Epub 2012 Jul 19. Review.

PMID:
22809423
45.

Novel concepts in evaluating antimicrobial therapy for bacterial lung infections in patients with cystic fibrosis.

Rogers GB, Hoffman LR, Döring G.

J Cyst Fibros. 2011 Dec;10(6):387-400. doi: 10.1016/j.jcf.2011.06.014. Epub 2011 Jul 19. Review.

46.

Does bacterial density in cystic fibrosis sputum increase prior to pulmonary exacerbation?

Stressmann FA, Rogers GB, Marsh P, Lilley AK, Daniels TW, Carroll MP, Hoffman LR, Jones G, Allen CE, Patel N, Forbes B, Tuck A, Bruce KD.

J Cyst Fibros. 2011 Sep;10(5):357-65. doi: 10.1016/j.jcf.2011.05.002. Epub 2011 Jun 12.

47.

Using bacterial biomarkers to identify early indicators of cystic fibrosis pulmonary exacerbation onset.

Rogers GB, Hoffman LR, Johnson MW, Mayer-Hamblett N, Schwarze J, Carroll MP, Bruce KD.

Expert Rev Mol Diagn. 2011 Mar;11(2):197-206. doi: 10.1586/erm.10.117. Review.

48.

Comparing the microbiota of the cystic fibrosis lung and human gut.

Rogers GB, Carroll MP, Hoffman LR, Walker AW, Fine DA, Bruce KD.

Gut Microbes. 2010 Mar;1(2):85-93. Epub 2010 Jan 29. No abstract available.

49.
50.

Electrophysiological evidence of enhanced performance monitoring in recently abstinent alcoholic men.

Padilla ML, Colrain IM, Sullivan EV, Mayer BZ, Turlington SR, Hoffman LR, Wagstaff AE, Pfefferbaum A.

Psychopharmacology (Berl). 2011 Jan;213(1):81-91. doi: 10.1007/s00213-010-2018-1. Epub 2010 Oct 13.

Supplemental Content

Loading ...
Support Center